MedTrace Logo

CIRSE Registry for LifePearl Microspheres

NCT03086096 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2026-05-13

No results posted yet for this study

Summary

The application of transarterial chemoembolisation (TACE) using LifePearl Microspheres loaded with Irinotecan in liver-only or liver-dominant metastatic disease in patients with colorectal adenocarcinoma will be observed. The registry has the following objectives:

1. map the exact indications that the device is being used for and at which stage in treatment it is being applied
2. to assess observed treatment outcomes in terms of safety and effectiveness as well as trying to determine any predictive response factors

Conditions

  • Colorectal Carcinoma
  • Neoplasm Metastasis

Interventions

DEVICE

LifePearl Microspheres loaded with Irinotecan

LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.

Sponsors & Collaborators

  • Cardiovascular and Interventional Radiological Society of Europe

    lead OTHER

Principal Investigators

  • Philippe Pereira, Prof. · Interventional Radiologist at SLK Klinikum Heilbronn GmbH, Germany

  • Julien Taieb, Prof. · Oncologist at Georges Pompidou European Hospital, Paris, France

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-02
Primary Completion
2021-08-31
Completion
2022-04-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03086096 on ClinicalTrials.gov